Body Pharm Tirzepatide 30 Pen

Body Pharm Tirzepatide 30 Pen: Price, Dosing & Comparison 2026

The Body Pharm Tirzepatide 30 Pen retails at R2,500 on Beskinny as of 2026 [1], making it a lower upfront cost option than the 60mg pen and branded Mounjaro for South African buyers tracking cost-per-mg. Whether that cost advantage holds depends on the concentration printed on your specific pen — which the public product listing does not state in mg/mL [1] — because a higher concentration per click means fewer injections per pen and a lower true cost-per-dose. Confirm the label before you buy.

Key Takeaways

• Body Pharm Tirzepatide 30 Pen costs R2,500 (2026) and suits the 2.5mg–5mg titration phase; the 60mg format offers 28% lower per-dose cost at maintenance doses of 5mg+.
• Standard tirzepatide dosing starts at 2.5mg weekly for four weeks, then steps up by 2.5mg every four weeks to a maximum of 15mg, with slow titration reducing nausea risk.
• Tirzepatide produced 22.5% mean body weight reduction at 15mg weekly in SURMOUNT-1 (Jastreboff et al., NEJM, 2022), compared to 14.9% for semaglutide 2.4mg in STEP-1 (Wilding et al., NEJM, 2021).
• Tirzepatide is a prescription-only medicine in South Africa; SAHPRA registration for Mounjaro or Zepbound could not be confirmed, and the Body Pharm pen carries no verified SAHPRA registration.
• Most side effects are gastrointestinal, dose-dependent, and peak during titration; nausea occurs in up to 31% of trial participants.

What Is the Body Pharm Tirzepatide 30 Pen?

The Body Pharm Tirzepatide 30 Pen is a 30mg tirzepatide dial-a-dose subcutaneous injection pen sold by Body Pharm (BP) as a research-grade/compounded peptide product, not branded Mounjaro or Zepbound [1]. It’s listed on Beskinny at R2,500 as of 2026 [1]. The exact concentration in mg/mL and total fill volume are not stated on the public product listing, so the label must be confirmed before purchase [1].

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist — the first molecule of its class approved for clinical use. In plain terms:

• GIP (glucose-dependent insulinotropic polypeptide) improves insulin sensitivity and influences fat storage and energy use.
• GLP-1 (glucagon-like peptide-1) slows gastric emptying, blunts appetite, and stimulates glucose-dependent insulin release.

That dual action is why tirzepatide has produced larger weight-loss numbers than single-agonist semaglutide in head-to-head obesity research, including SURMOUNT-5 [5]. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) showed 22.5% mean body weight reduction at 15mg weekly over 72 weeks, compared to 14.9% for semaglutide 2.4mg in STEP-1 (Wilding et al., NEJM, 2021) — a 7.6 percentage point gap attributable to GIP receptor activation. If you want to compare molecules directly, the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen are the GLP-1-only counterparts stocked alongside it.

Regulatory status: what BP is and isn’t

The branded tirzepatide products (Mounjaro for type 2 diabetes, Zepbound for obesity) are Eli Lilly pharmaceuticals registered through formal regulators in their home markets. The Body Pharm 30 Pen is not Mounjaro and not Zepbound — it’s a separately manufactured compounded/research peptide carrying the same active molecule [1].

SAHPRA registration of Mounjaro or Zepbound in South Africa is [unverified] in the sources reviewed for this article, and no SAHPRA registration is claimed for the Body Pharm pen itself [1][2][3][4]. Under the Medicines and Related Substances Act, tirzepatide is a prescription-scheduled medicine, so purchase, import and self-injection should be cleared with a registered SA pharmacist or prescriber before you place an order.

30mg Pen vs. 60mg Pen vs. Mounjaro: Cost Per Dose 2026

The Body Pharm 60mg pen wins on cost-per-dose at maintenance levels (5mg+), while the 30mg pen is cheaper per injection during the 2.5mg titration phase. Branded Mounjaro pricing in South Africa is [unverified] across the sources reviewed for this article, so the table below treats it as a “confirm locally” line rather than a quoted retail figure [2][3][4].

Product	Total Tirzepatide	Approx. Price (ZAR, March 2026)	Doses at 2.5mg	Doses at 5mg	Doses at 10mg	Cost/dose at 5mg
Body Pharm 30mg Pen	30mg	R2,500 [1]	12	6	3	~R417
Body Pharm 60mg Pen	60mg	~R3,600 [unverified]	24	12	6	~R300
Mounjaro (SA clinic/script)	2.5–15mg/pen, multi-pen box	[unverified] in SA [2][3][4]	—	—	—	—

The 30mg pen at R2,500 [1] gives roughly R208 per 2.5mg starter dose across 12 weekly injections — useful if you’re spending the first three months at 2.5mg and reassessing before committing to a larger pen. Once you titrate to 5mg or 10mg weekly, the 60mg format drops your per-dose cost by around 28% on the figures above, assuming the R3,600 listing is current at purchase.

How we calculated cost per dose

We took the listed retail price, divided by the total tirzepatide milligrams in the pen, then multiplied by the target weekly dose. No wastage, priming loss, or expiry-driven discard is built in — real-world cost per dose runs slightly higher because pens have a 28–30 day in-use stability window on most GLP-1 labels [unverified for Body Pharm specifically]. Confirm the actual mg/mL concentration on the pen label before relying on these dose counts; the Beskinny product listing does not publish concentration or fill volume [1].

When the 30mg pen still makes sense

If you’re new to tirzepatide, the smaller pen is the lower-risk financial entry point because you’re not locked into a R3,600 outlay before knowing how you tolerate the molecule. Buyers cross-shopping GLP-1 options can compare the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen on the same per-dose basis before settling on a molecule.

Prices verified March 2026 [1]; marketplace listings change without notice — screenshot the product page at checkout.

Tirzepatide Dosing Schedule: Titration Guide for 2026

The standard tirzepatide titration starts at 2.5mg weekly and steps up by 2.5mg every four weeks until you reach a tolerable maintenance dose between 5mg and 15mg. Slow titration matters because it blunts the GI side effects — nausea, vomiting, diarrhoea, constipation — that drive most early discontinuations. SURMOUNT-1 reported nausea in up to 31% of participants, with rates highest during the first four weeks at 2.5mg [5].

Phase	Weekly dose	Purpose
Week 1–4	2.5mg	Initiation — not therapeutic, body adapts
Week 5–8	5mg	First therapeutic dose
Week 9–12	7.5mg	Step-up if tolerated and more effect needed
Week 13–16	10mg	Common maintenance dose
Week 17–20	12.5mg	Step-up if weight/HbA1c targets not met
Week 21+	15mg	Maximum dose used in SURMOUNT-1

SURMOUNT-1 (Jastreboff et al., NEJM, 2022) reported a mean weight loss of 22.5% at 15mg over 72 weeks in adults with obesity. That outcome assumed full titration to the 15mg maintenance dose plus lifestyle intervention (500 kcal/day deficit and 150 minutes of weekly physical activity), not 2.5mg held indefinitely.

Why the 30mg pen fits the early titration window

The Body Pharm 30mg pen covers the first 12 weeks comfortably if you stay at 2.5mg (12 doses = 30mg total), or roughly 6 weeks if you move quickly to 5mg. That makes it the right format for weeks 1–8, after which most users either step up to the 60mg pen for 7.5mg+ maintenance or switch molecules. Buyers weighing semaglutide instead can price-check the Body Pharm Semaglutide 6 Pen or HD Semaglutide 10 Pen against the same titration logic, though semaglutide tops out at 2.4mg weekly with its own schedule.

Important dosing caveats

This schedule is based on the FDA-approved Mounjaro prescribing information and may not apply directly to compounded or research-grade pens where concentration per click is [unverified for Body Pharm specifically] [4]. Do not self-titrate without a prescriber reviewing your tolerance, blood glucose if diabetic, and any concurrent medications. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis, stop dosing and seek medical care.

How to Inject the Body Pharm Tirzepatide Pen: Step-by-Step

Inject the Body Pharm pen subcutaneously once weekly using its dial-a-dose mechanism, which works differently to the Mounjaro KwikPen auto-injector and should not be operated by following Mounjaro tutorial videos. The fat-freeze.co.za listing confirms the Body Pharm format as a “convenient dial-a-dose” pen, meaning you manually select the dose and press the plunger rather than triggering a single pre-set click as with the branded device.

Before your first injection, confirm needle compatibility with the seller because the Beskinny product page does not specify whether the pen accepts standard insulin pen needles or a proprietary fitting [unverified] [1]. Using the wrong gauge or length can affect both dose accuracy and tissue depth. Ask for a photo of the box showing needle thread type and concentration in mg/mL before you dose.

The 11-step weekly injection routine

1. Gather a clean surface, the pen, a fresh needle (if compatible), an alcohol swab, and a sharps container.
2. Wash hands with soap and warm water for 20 seconds.
3. Remove the pen cap and inspect the solution through the window. It should be clear and colourless. Discard if cloudy, discoloured, or containing particles.
4. Attach the needle (if applicable) and dial the dose window to your prescribed amount, for example 2.5mg for weeks 1–4.
5. Choose a site: abdomen at least 5cm from the navel, upper outer thigh, or back of the upper arm.
6. Clean the site with the alcohol swab in a single outward spiral and let it air-dry for 10 seconds. Wet alcohol stings on entry.
7. Pinch a 2–3cm fold of skin. Insert the needle at 90° for most adults, or 45° if you are lean with minimal subcutaneous fat.
8. Press the plunger fully and steadily. Do not rush it.
9. Hold the needle in place for 5–10 seconds after the plunger bottoms out to let the full dose deliver.
10. Withdraw straight out and drop the needle into a sealed sharps container. No recapping.
11. Rotate sites weekly. If you used left abdomen this Sunday, use right thigh next Sunday.

Storage between doses

Refrigerate the pen at 2–8°C. Peptides degrade at room temperature, and freezing destroys the molecular structure. Don’t store on the fridge door where temperature swings are largest. If left at room temperature, follow the manufacturer’s in-use stability window on the box. The Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen follow the same cold-chain rules but have their own dosing schedules.

Tirzepatide for Weight Loss: Clinical Evidence

Tirzepatide produces the largest mean weight loss of any pharmacotherapy currently in clinical use. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) showed 22.5% mean body weight reduction at the 15mg weekly dose over 72 weeks in adults with a BMI ≥30, or ≥27 with a weight-related comorbidity. That is the number to anchor your expectations to before going further.

For context, semaglutide 2.4mg in STEP-1 (Wilding et al., NEJM, 2021) delivered a mean 14.9% reduction over 68 weeks in a comparable population. Tirzepatide’s edge is widely attributed to its dual GIP/GLP-1 receptor agonism, which appears to improve insulin sensitivity beyond what single GLP-1 agonism achieves, partially independently of the weight loss itself — a mechanism difference that translates to roughly 7.6 percentage points more weight loss in head-to-head comparison.

Tirzepatide vs semaglutide at a glance

Metric	Tirzepatide 15mg (SURMOUNT-1, 2022)	Semaglutide 2.4mg (STEP-1, 2021)
Mean body weight reduction	22.5%	14.9%
Trial duration	72 weeks	68 weeks
Mechanism	Dual GIP/GLP-1 agonist	GLP-1 agonist
Weekly injection	Yes	Yes
Population	BMI ≥30, or ≥27 with comorbidity	BMI ≥30, or ≥27 with comorbidity

If you are weighing the semaglutide route instead, the Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen sit in the same weekly-injection category but follow the lower STEP-1 efficacy curve.

Realistic expectations for South African buyers

Trial participants were not magicians. They followed a 500 kcal/day deficit and 150 minutes of weekly physical activity under clinical supervision, with regular dose escalation and side-effect management. Real-world loss tends to land below the trial mean when adherence slips, when titration stalls at 5mg or 7.5mg due to nausea, or when diet is unchanged.

Individual response varies by 10 percentage points or more in either direction. A useful planning number is 15–18% loss over 12 months at maintenance doses of 10–15mg weekly, assuming you tolerate titration and adjust eating accordingly. Anything beyond that is upside, not the baseline you should be paying R2,500 a pen to chase.

Tirzepatide for Type 2 Diabetes and Blood Sugar Control

Tirzepatide lowers blood sugar through two receptors at once: GLP-1 agonism triggers glucose-dependent insulin release and suppresses glucagon, while GIP agonism improves insulin sensitivity and blunts postprandial glucose spikes. That dual action is why HbA1c reductions in the SURPASS programme outpaced what single GLP-1 agonists achieved in comparable T2DM populations.

In SURPASS-1 (Rosenstock et al., NEJM, 2021), tirzepatide monotherapy reduced HbA1c by up to 2.07 percentage points from baseline at the 15mg dose over 40 weeks in drug-naïve adults with type 2 diabetes. The FDA approved tirzepatide for T2DM in May 2022 under the Mounjaro brand because this HbA1c reduction exceeded the 1.5 percentage point threshold typically required for regulatory approval. Mean fasting serum glucose dropped by roughly 43–49 mg/dL at the higher doses, and more than half of 15mg participants reached HbA1c below 5.7%, the non-diabetic range.

Where tirzepatide pulls ahead of semaglutide for diabetics

Head-to-head mechanistic work suggests tirzepatide produces larger gains in total insulin secretion rate and peripheral insulin sensitivity than semaglutide at matched HbA1c reductions, with comparable effects on gastric emptying. The specific trial citation referenced on the Body Pharm product page is [unverified] in the sources available to me [1], so confirm it with your prescriber before using it as a clinical decision point.

Endpoint (T2DM, dose-matched comparators)	Tirzepatide signal
HbA1c reduction vs placebo, SURPASS-1, 15mg, 40 weeks	Up to 2.07 pp
Insulin sensitivity vs semaglutide	Greater improvement (mechanism trial [unverified])
Gastric emptying delay	Comparable to single GLP-1 agonists
FDA T2DM approval	May 2022

If you are diabetic, this is not a self-medicate situation. South African T2DM management requires a prescription, baseline HbA1c and renal function bloods, and dose titration supervised by a clinician who can adjust your sulphonylurea or insulin to avoid hypoglycaemia. Compounded or research-grade peptide pens purchased online sit outside that pathway, and the legal status under the Medicines and Related Substances Act is [unverified] but restrictive. Compare the semaglutide route via the Body Pharm Semaglutide 6 Pen or HD Semaglutide 10 Pen only with the same medical supervision in place.

Body Pharm Tirzepatide vs. Semaglutide: Which Should You Choose?

Tirzepatide is the stronger choice if your priority is maximum weight loss. Semaglutide is the more conservative pick if you want the longer real-world tolerability record. Both require a prescription pathway in South Africa, and neither molecule has a verified SAHPRA registration confirmed in the sources available here [unverified].

The mechanism difference is the headline. Tirzepatide activates both GIP and GLP-1 receptors. Semaglutide activates GLP-1 alone. That dual action is what drove the SURMOUNT-1 result (Jastreboff et al., NEJM, 2022) of 22.5% mean body weight reduction at 72 weeks on 15mg weekly, against STEP-1 (Wilding et al., NEJM, 2021) semaglutide 2.4mg producing 14.9% over 68 weeks. SURMOUNT-5, published in 2025, confirmed tirzepatide outperformed semaglutide head-to-head [unverified exact percentage spread] [2].

Factor	Tirzepatide	Semaglutide
Mechanism	Dual GIP/GLP-1 agonist	GLP-1 agonist only
Weight loss (pivotal trial)	22.5% (SURMOUNT-1, 2022)	14.9% (STEP-1, 2021)
Blood sugar control	Greater HbA1c reduction in SURPASS programme	Strong, well-established
Body Pharm pen on beskinny.store	Body Pharm Tirzepatide 30 Pen	Body Pharm Semaglutide 6 Pen
Approx. price (2026)	R2,500 [1]	See product page [unverified]

Tolerability is the swing factor. Some users report less nausea on semaglutide at matched-efficacy doses, which is why the HD Semaglutide 10 Pen remains a popular option for first-time GLP-1 users. If you want both molecules in a single device, the HD Tirsema 44 Pen combines tirzepatide and semaglutide, though combination peptide therapy carries its own dosing and side-effect considerations that should be reviewed with a prescriber before purchase.

Side Effects and Safety: What to Expect

Most tirzepatide side effects are gastrointestinal, dose-dependent, and peak during titration. The figures below come from the SURPASS and SURMOUNT programmes as captured in the Mounjaro FDA prescribing information (2022/2023). Compounded or research-grade products like the Body Pharm pen may vary in purity and impurity profile, which can shift the real-world side-effect picture [unverified].

Side effect	Reported incidence (branded tirzepatide, SURPASS/SURMOUNT)
Nausea	up to 31%
Diarrhoea	up to 22%
Vomiting	up to 13%
Constipation	~10%
Decreased appetite	common, dose-related
Injection site reaction	uncommon
Pancreatitis	rare, serious
Gallbladder disease	rare, serious
Hypoglycaemia	mainly when combined with insulin or sulfonylureas

Slow titration (2.5mg for 4 weeks, then 5mg, then stepping up monthly) is the standard mitigation for nausea and vomiting because it allows your GI tract to adapt to the peptide’s effects on gastric emptying. If you have stacked side effects on tirzepatide, switching molecules is a real option. The Body Pharm Semaglutide 6 Pen and HD Semaglutide 10 Pen are the same-category alternatives most South African buyers consider.

Absolute contraindications

Do not use tirzepatide if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) because GLP-1 agonists have been shown to increase MTC risk in animal models, and human safety data remain limited. Caution also applies in active pancreatitis, severe gastroparesis, and pregnancy.

Medical disclaimer: This article is informational and not medical advice. Tirzepatide is a prescription-only medicine. Consult a registered South African doctor or pharmacist before starting, switching, or stopping any GLP-1/GIP therapy. Do not self-prescribe.

Buying Tirzepatide Online in South Africa: What to Know in 2026

Tirzepatide is a prescription-only medicine in South Africa, and buying it online without a valid prescription sits in a legally grey-to-restricted zone under the Medicines and Related Substances Act 101 of 1965 [unverified]. SAHPRA (the South African Health Products Regulatory Authority) regulates medicine registration, scheduling, and import controls, so any peptide bought outside the regulated dispensing chain carries personal regulatory risk.

Branded Mounjaro availability through South African pharmacies appears fragmented as of early 2026, and we could not confirm a SAHPRA-registered retail channel from the sources reviewed [unverified][1][3]. Most local buyers therefore end up choosing between compounded or research-grade pens like the Body Pharm 30mg, listed on beskinny.store at R2,500 [2], or the larger 60mg format. Body Pharm products are sold as research-grade peptides, and buyers should verify the legal status for their intended use with a registered South African pharmacist or prescriber before purchasing.

Practical buyer checklist

• Confirm the seller will supply a batch/COA (Certificate of Analysis) on request, and photograph the box (concentration in mg/mL, total volume, expiry) before first use.
• Speak to a registered SA doctor or pharmacist about titration, contraindications, and interaction with any current medication.
• Compare alternatives in the same category — the Body Pharm Semaglutide 6 Pen, HD Semaglutide 10 Pen, and the full weight loss injections range — before committing.
• Treat marketplace prices as snapshot figures.

Prices and listings correct as of February 2026 and subject to change without notice.

Frequently Asked Questions

Question	Short answer
Doses per 30mg pen	Depends on weekly dose; confirm mg/mL on box [unverified][1]
30mg vs 60mg pen	60mg holds roughly double the tirzepatide content
Non-diabetic weight loss use	Off-label; requires SA prescriber sign-off
Storage	2–8°C refrigerated, do not freeze
Mounjaro equivalence	Same molecule, different manufacturer and regulation
Starting dose	2.5mg weekly for 4 weeks (Mounjaro PI, 2022)

Q1: How many doses are in the Body Pharm Tirzepatide 30mg pen?

The dose count depends on your weekly dose and the exact mg/mL concentration printed on the pen, which the Beskinny product listing does not publish [unverified][1]. At a 2.5mg starting dose, 30mg of tirzepatide gives 12 weekly doses in theory. Confirm the total fill volume on the box before assuming.

Q2: What is the difference between the 30mg and 60mg Body Pharm tirzepatide pen?

The 60mg pen contains roughly double the tirzepatide of the 30mg pen, so it suits buyers titrating up to 10mg or 15mg weekly without re-ordering. The 30mg pen at R2,500 [1] is the lower upfront-cost entry point and matches the 2.5mg–5mg titration phase.

Q3: Can I use the Body Pharm tirzepatide pen for weight loss if I don’t have diabetes?

Tirzepatide is used off-label for weight loss in non-diabetic adults, but in South Africa this requires a registered prescriber’s assessment and ongoing supervision. SURMOUNT-5 (2025) confirmed tirzepatide produced greater weight loss than semaglutide head-to-head [unverified exact figures][5]. Compare against the Body Pharm Semaglutide 6 Pen before deciding.

Q4: How should I store the Body Pharm tirzepatide pen?

Store the pen at 2–8°C in a refrigerator, away from the freezer compartment. Freezing destroys peptide structure and makes the product unusable. Keep the pen capped, away from direct light, and check the solution is clear and colourless before each injection.

Q5: Is tirzepatide the same as Mounjaro?

Tirzepatide is the active molecule; Mounjaro is Eli Lilly’s branded, regulator-approved version. Body Pharm pens contain tirzepatide as a research-grade or compounded product, not branded Mounjaro. SAHPRA registration for Mounjaro in South Africa could not be confirmed from the sources reviewed [unverified][4].

Q6: What is the starting dose for tirzepatide?

The standard starting dose is 2.5mg once weekly for the first four weeks, then increased to 5mg weekly, per the original Mounjaro prescribing information (2022). Titration continues in 2.5mg increments every four weeks up to a maximum of 15mg, based on tolerance and clinical response. The HD Semaglutide 10 Pen follows a different titration schedule.

Next Steps

Before purchasing the Body Pharm Tirzepatide 30 Pen, consult a registered South African doctor or pharmacist to confirm the legal and medical pathway for your use case, request a Certificate of Analysis from the seller, and compare the cost-per-dose against the 60mg format and semaglutide alternatives on beskinny.store. Once you have prescriber clearance and the pen in hand, photograph the label to verify concentration and expiry, then follow the 11-step injection routine above, rotating injection sites weekly and storing the pen at 2–8°C between doses.